252 related articles for article (PubMed ID: 28551401)
1. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
[TBL] [Abstract][Full Text] [Related]
2. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
[TBL] [Abstract][Full Text] [Related]
3.
Harlos C; Metser U; Poon R; MacCrostie P; Mason W
Curr Oncol; 2019 Aug; 26(4):e458-e465. PubMed ID: 31548813
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.
Kristensen SB; Hess S; Petersen H; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2056-63. PubMed ID: 26194717
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
6. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
[TBL] [Abstract][Full Text] [Related]
7. Whole-Body
Sheikhbahaei S; Marcus CV; Fragomeni RS; Rowe SP; Javadi MS; Solnes LB
J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
[TBL] [Abstract][Full Text] [Related]
8. Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.
Pena Pardo FJ; García Vicente AM; Amo-Salas M; López-Fidalgo JF; Garrido Robles JA; de Ayala Fernández JÁ; Del Saz Saucedo P; Muñoz Pasadas M; Soriano Castrejón A
Clin Transl Oncol; 2017 Jan; 19(1):111-118. PubMed ID: 27139696
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
10. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
[TBL] [Abstract][Full Text] [Related]
11. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
Patel RR; Subramaniam RM; Mandrekar JN; Hammack JE; Lowe VJ; Jett JR
Mayo Clin Proc; 2008 Aug; 83(8):917-22. PubMed ID: 18674476
[TBL] [Abstract][Full Text] [Related]
12. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
13. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit.
Hadjivassiliou M; Alder SJ; Van Beek EJ; Hanney MB; Lorenz E; Rao DG; Sharrack B; Tindale WB
Acta Neurol Scand; 2009 Mar; 119(3):186-93. PubMed ID: 18855873
[TBL] [Abstract][Full Text] [Related]
14. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings.
Masangkay N; Basu S; Moghbel M; Kwee T; Alavi A
Nucl Med Commun; 2014 Oct; 35(10):1038-46. PubMed ID: 25023997
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis.
Bannas P; Weber C; Derlin T; Lambert J; Leypoldt F; Adam G; Mester J; Klutmann S
Eur Radiol; 2010 Apr; 20(4):923-30. PubMed ID: 19789881
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
18.
García Vicente AM; Delgado-Bolton RC; Amo-Salas M; López-Fidalgo J; Caresia Aróztegui AP; García Garzón JR; Orcajo Rincón J; García Velloso MJ; de Arcocha Torres M; Alvárez Ruíz S;
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1575-1587. PubMed ID: 28550611
[TBL] [Abstract][Full Text] [Related]
19. 18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography can reliably rule-out infection and cancer in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis suspected of disease relapse.
Frary EC; Hess S; Gerke O; Laustrup H
Medicine (Baltimore); 2017 Jul; 96(30):e7613. PubMed ID: 28746217
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
